2cureX AB (publ)
STO: 2CUREX.ST0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Stockholm Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Nathaniel Hutley
- Employees
- 14
- Headquarters
- Copenhagen, Denmark
- IPO year
- 2017
- Market cap
- SEK 44.4M
- Website
- https://www.2curex.com
Loading 2CUREX…
Loading profile data…Frequently asked questions about 2CUREX
What does 2cureX AB (publ) (2CUREX.ST) do?
2cureX AB (publ) operates as a medtech company in Europe. Its principal product is IndiTreat, an IVD test, which helps to predict cancer patient's response and resistance to different drugs and select the appropriate treatment. The company is also conducting various clinical programs for IndiTreat for breast colorectal, ovarian, and pancreatic c...
Where does 2CUREX.ST trade?
2cureX AB (publ) (2CUREX.ST) trades on the Stockholm Stock Exchange.
What sector is 2CUREX.ST in?
2cureX AB (publ) (2CUREX.ST) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of 2cureX AB (publ)?
Nathaniel Hutley is the chief executive officer of 2cureX AB (publ) (2CUREX.ST).
Where is 2cureX AB (publ) headquartered?
2cureX AB (publ) is headquartered in Denmark.
Does 2CUREX.ST pay a dividend?
Yes — 2cureX AB (publ) (2CUREX.ST) paid a trailing twelve-month dividend of SEK 0.08 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 2CUREX.ST go public?
2cureX AB (publ) (2CUREX.ST) completed its initial public offering in 2017.